Entering text into the input field will update the search result below

GlaxoSmithKline granted FDA nod for prefilled syringe of Nucala in eosinophilic asthma

Jan. 24, 2022 11:52 AM ETGSK plc (GSK) StockBy: Dulan Lokuwithana, SA News Editor

Four Injured In Explosion At GlaxoSmithKline Factory

Jeff J Mitchell/Getty Images News

  • GlaxoSmithKline (NYSE:GSK) announced that the FDA approved 40 mg prefilled syringe of Nucala (mepolizumab) for children aged 6 – 11 years with severe eosinophilic asthma (SEA).
  • Nucala is indicated as an add-on, prescription maintenance treatment

Recommended For You

More Trending News

About GSK Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
GSK--
GSK plc